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Abstract
Background: Urinary tract infection (UTI) remains one of the main complications after kidney transplantation and it
has serious consequences.
Methods: Fifty-two patients with kidney transplantation were evaluated for UTI at 3-145 days (mean 40.0 days)
after surgery.. Forty-two received a graft from a live donor and 10 from a deceased donor. There were 22 female
and 30 male patients, aged 11-47 years. Microscopic examinations, leukocyte esterase stick, and urinary culture
were performed every third day and weekly after hospitalization. A positive culture was consider when patients
presented bacterial counts up to 10
5 counts.
Results: UTI developed in 19/52 (37%) patients at 3-75 days (mean 19.5 days after transplantation. Recurrent
infection was observed in 7/52 (13.4%) patients at days 17-65. UTI was more frequent in patients who received
deceased grafts compared with live grafts (7/10, 70% vs. 12/42, 28%; p < 0.007). Female patients were more
susceptible than male (11/22, 50% vs. 8/22, 36.35%; p < 0.042). Five-year survival rate was 94.5% (49/52 patients).
Kidney Graft exit update is 47/52 (90.2%), and there were no significant differences between graft rejection and UTI
(p = 0.2518). Isolated bacteria were Escherichia coli (31.5%), Candida albicans (21.0%) and Enterococcus spp. (10.5%),
followed by Pseudomonas aeruginosa, Klebsiella pneumoniae, Morganella morganii, Enterobacter cloacae and
Micrococcus spp. Secondary infections were produced by (7/19, 36.8%). Enterococcus spp. (57%), E. coli (28%) and
Micrococcus spp. (14.2%). Antibiotic resistance was 22% for ciprofloxacin and 33% for ampicillin. Therapeutic
alternatives were aztreonam, trimethoprim-sulfamethoxazole, netilmicin and fosfomycin.
Conclusions: Surveillance of UTI for the first 3 months is a good option for improving quality of life of kidney
transplantation patients and the exit of graft function especially for female patients and those receiving deceased
grafts. Antibiograms provided a good therapeutic alternative to patients who presented with UTIs after receiving a
kidney allograft.
Background
Treatment for patients with severe renal failure has been
improved, especially with better surgical procedures and
pharmaceutical management. Nevertheless, since these
patients require immunosuppressive therapy, they are
vulnerable to developing postoperative infections.
Among these, urinary tract infections (UTI) are the
most frequently observed and have high morbidity
[1-3,5,6]. UTI was observed in 54.2% of 149 patients in
Iran [7]. The frequency of UTI has varied between
studies. A study in Tunisia has reported a UTI incidence
of 43% within the first month and 33% for up to
6m o n t h s[ 8 ] . [ In France, Pellé et al [9] have reported
UTI in 77% of 177 patients who had undergone kidney
transplantation. UTI after kidney transplantation has
been associated with patient mortality and graft failure
[10]. Nampoory et al [11] have recommended surveil-
lance for UTI for a period of 6 months, to diminish the
risk of renal failure. Charfeddine et al. [8] have reported
that UTI was observed in all patients with graft rejection
and 58% of patients without rejection.. Akinalow et al
[12] have described UTI as an important risk factor for
mortality in kidney transplantation patients.
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ted as an important cause of graft rejection [7], there-
fore, recipients always receive antiviral therapy, before
and after surgery for prophylaxis. In addition, bacterial
infections have high morbidity and mortality and should
not be discounted [7]. Several species of bacteria that
cause UTI in kidney transplant patients have been iso-
lated. Escherichia coli has been reported as the main
uropathogen isolated in UTI among transplant patients
in studies in Spain, India and Kuwait [11,13-15]. Kleb-
siella spp., Pseudomonas spp., including P. aeruginosa,
and multiresistant isolates of E. coli, may by important
etiological agents of these infections Gram-positive bac-
teria may also be important etiological agents of UTI,
and the most frequently isolated have been Enterocooc-
cus spp. and Staphylococcus aureus [4,11,14-17]. Less
frequently, Corynebacterium urealyticum is considered
as an etiological agent.
Infections caused by Candida spp. may be a serious
problem in transplant recipients. They might cause
infections of the bloodstream that can lead to sepsis.
Such infection is caused frequently by catheter coloniza-
tion and is improved with catheter removal. Candida
albicans must be diagnosed rapidly because it may have
fatal consequences [18,19].
Urinary culture, with microscopic examination and
leukocyte esterase stick, has been recommended as a
good predictor of symptomatic UTI [20]. Urinary cul-
ture in kidney transplant patients has been questionable,
as a result of its cost, and it may be replaced with
microscopic examination and the leukocyte esterase
stick. Nevertheless, it is advisable to carry out urinary
culture on kidney transplant patients within the first few
months, because of their extreme vulnerability to UTI.
Furthermore, urinary culture gives the opportunity of
performing an antibiogram, which can lead to appropri-
ate medical treatment. In fact, appropriate antibiotic
therapy might give the patients a greater probability of
preserving graft function [21,22].
This study aimed to establish the frequency of UTI in
kidney transplant patients at Hospital Juárez de México,
evaluate the greatest risk factors for developing UTI,
and offer the physician and patient a good diagnosis and
appropriate antibiotic therapy.
Methods
Study design
This was a prospective, clinical, noninvasive study. Fifty-
two patients who underwent kidney transplantation at
Hospital Juárez of México between November 1999 and
October 2001 were included. Forty-two patients (22
female, 10 male, aged 11-47 years) received a graft from
a living related donor and 10 from a deceased donor. A
Foley catheter was installed before surgery, and it
remains from 10 to 14 days afterwards. After surgery
patients received an immunosuppressive treatment with
prednisone, cyclosporine and azatioprine. All patients
take as prophylactic treatment cefalosporine 2 genera-
tion 1.5 g/day for 10 days, aciclovir 400 mg and nitasta-
tine 100 000 u each six hours for three months. Urinary
samples were recovered directly from the catheter at 24-
48 hours after surgery, and then every third day
throughout the hospitalization period. Afterwards,
patients were given sterile material and invited to take
first morning sterile urine sample to the microbiology
research laboratory each then days, when attending the
Hospital for its usual medical control or cyclosporine
detection levels at the HLA research laboratory.
Ethical considerations
This study commenced following approval of the
Research and Ethical Committees of the Hospital Juárez
of México. Consent letters were not necessary because
t h i ss t u d yd i dn o ti n v o l v ea n yi n v a s i v ep r o c e d u r e sf o r
the patients. Patients were informed orally about the
study and voluntary participation was offered after treat-
ment of UTIs. The required sterile specimens were pro-
vided by the microbiology research laboratory and the
cultures did not incur any financial costs for the
patients.
Urinary studies
Qualitative urinary cultures were done on blood agar,
MacConkey agar and Biggy agar. as described previously
[20] Cultures were incubated at 37°C for 24 hours.
BiGGY plates were incubated for 72 hours. Urinary
samples were evaluated with the leukocyte esterase
stick, using Multistix 10 SG reagent strips (Bayer Diag-
nostics, S.A. de C.V., México, D.F.). Microscopic urinary
sediment examinations were done after centrifugation of
the sample at 1000 g for 15 minutes on a clinical centri-
fuge (Clay Adams Dynac, Beckton Dickinson Co.).[Par-
sippant N.J. 07054] Epithelial cells, urinary crystals and
the number of leukocytes per microscopic field were
recorded [20]. Urinary studies were performed every
third day and weekly after hospital discharge. It was
considered a positive result for Urinary tract infection
[UTI], when bacterial counts were recorded up to 10
-5
counts, and leukocytes were up to 10 per microscopic
field. Positive nitrates value was recorded for Gram
negative bacteria. Lower bacterial counts were consid-
ered as bacteriuria, and they were not considered for
the purpose of this study
Susceptibility studies
Positive urinary cultures were processed for antimicro-
bial susceptibility testing on Mueller-Hinton agar plates,
using the Kirby-Bauer disk diffusion method, according
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were evaluated against ciprofloxacin, aztreonam, ampi-
cillin, gentamicin, cefoperazone, arbenicillin, kanamycin,
tetracycline, norfloxacin, aztreonam, trimethoprim-sulfa-
methoxazole, netilmicin and fosfomicin. Enterococcus
spp. were evaluated against ampicillin, cefotaxime, peni-
cillin, erythromycin, ceftriaxone, trimethoprim-sulfa-
methoxazole, and vancomycin. Susceptibility tests were
performed employing commercial Sensi-Discs from BD-
BBL, Becton Dickson Company Sparks, MD 21152,
USA.
Statistical analysis
Studies were evaluated with the Χ
2 test. Statistical analy-
sis was performed with Graph-Pad version 2.01
software.
Results
Patient surveillance
Patients were evaluated for UTI from 3 to 150 days
(mean 40.75 ± 40.0, arithmetic mode 40 days) after sur-
gery. Four patients could not continue their evaluation
beyond the first period as they lived outside Mexico
City Other patients, continued voluntarily with micro-
biological evaluation for up to 3 months.
UTI
UTIs were recorded in 19/52 (37%) patients. UTI was
present as early as day 3 and as late as day 75, with a
mean of 19.5 days. Reinfection was observed in 7/19
(36.8%) patients with previous UTI, from day 17 to 65.
These infections were more frequent among patients
who received a deceased graft compared with a graft
from a live donor, as it is shown on Figure 1. Female
patients were more susceptible to UTI than male
patients (11/22, 50% vs. 8/30, 22%; p = 0.045). Forty-
nine of 52 patients (94.5%) survived for up to 5 years.
The graft exit monitoring up to 7 is descrived on (Table
1). Rejetion within UTI or not UTI, was higher,
but these results were not statistically significant
(p = 0.2518) (Table 2).
Microbiological results
The first infections developed were caused mainly by
E. coli, C. Albicans, Enterocoocus spp., and Enterobacter-
iaceae (Table 3). The secondary infections were caused
mainly by Enterococcus spp. (3/7, 47%), E. coli (2/7,
28.5%) and Micrococcus spp. (1/7, 14.28%).
Antimicrobial agents
The most recommended antibiotics for kidney trans-
plant patients were ciprofloxacin and ampicillin. Cipro-
floxacin resistance was observed among 22% of isolated
strains, and ampicillin resistance among 33% of the iso-
lated Gram-negative bacteria. Therapeutic alternatives
for these cases were aztreonam, trimethoprim-sulfa-
methoxazole, netilmicin and fosfomycin. A multiresis-
tant Enterococcus was recovered, which was sensitive
only to vancomycin.
Discussion
This work demonstrated that, despite prophylactic treat-
ment of kidney transplant patients, UTI was a major
postoperative complication. Nineteen of 52 patients
(37%) developed at least one episode of UTI. These
results are similar to those of Kanisauskaite et al [23],
who reported UTI in 37% of 57 patients, and Memiko-
glu [4], who found UTI in 41% of 136 patients in Tur-
key. However, these numbers of patients are lower than
those reported by Poumard et al [7], who found UTI in
54% of 179 patients in Iran. These works state up the
need of including studies of infectious diseases besides
the renal function tests after kidney transplantation.
In the present study, we found that patients who
received a deceased graft were more susceptible to UTI,
compared with a graft from a living related donor (70%
vs. 28%), and may reflect an asymptomatic infection in
the cadaver donor which developed in the immunosup-
pressed patient; in contrast, live donors are evaluated
carefully before surgery. Similar results have been
reported by Midtvedt et al [24], who reported that
deceased kidney recipients had higher rates of infections.
In the present study, female sex was found to be a risk
factor for UTI, as reported previously [4].
It has been proposed that surveillance of UTI in kid-
ney transplant patients should be performed over a long
period. Kumar et al [21] have suggested evaluation over
the first 100 days, and Dupont et al [25] have reported
that late UTI may damage renal allografts at more than
a year after surgery. We found UTI between 3 and
75 days after surgery, therefore, we confirm that surveil-
lance should be carried out for 3 months after kidney
transplantation.
Figure 1 Urinary tract infections with cadaveric or living
donors. Frequency of UTI among patients who received a
deceased or live donor grafts. p = 0.007 (Χ
2 test)
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evaluation of cyclosporine levels at the HLA research
laboratory, as well as medical evaluation. The 5-year
survival was 94.5% (49/52 patients), and 47 patients
have survived to the present. The graft exit up to seven
years was 47/52 [90.2%]. This result is higher than that
reported by Kanisauskaite et al [23] in Lithuania, who
had 85% of kidney survival exit.
In our patients, E. coli was the main agent that caused
UTI after kidney transplantation,[table 3] and the infec-
tive agent in one of the three patients who suffered kid-
ney allograft rejection, which is similar to several other
studies from around the world [4,11,14,15,19]. The sec-
ond major cause of infection in our patients was C. albi-
cans, which was cultured from four patients, two of
whom developed reinfection with Enterococcus spp. and
E. coli. C. albicans infection in our patients was more
common than that observed by Valera et al in Spain
[15]. Candida infection can have serious consequences
if it is not detected early. Catheter removal and ampho-
tericin B is a good therapeutic option for these patients
[18]. Unfortunately, one of the four patients infected
with Candida spp. suffered graft rejection before day 10.
S. aureus is one of the most important microorgan-
isms that causes UTI in transplant patients but it was
not observed in the present study [26,27]. Among the
Gram-positive bacteria, the main organism observed in
our study was D enterococci, both in primary and sec-
ondary infections. One of the patients infected with this
bacterium suffered allograft rejection before day 10.
These results are in agreement with previously pub-
lished studies. Alangaden [13] and Leigh et al. [26], have
designated Enterococcus spp. as an emerging bacterium
that causes symptomatic infections, especially in kidney
transplant patients.
The cost-benefit of urinary cultures has been ques-
tioned, especially in asymptomatic UTI in kidney trans-
plant patients [28]. It is thus advisable to conduct
additional studies to evaluate the advantages of perform-
ing cultures in all post-transplant patients for UTI
surveillance.
In contrast, it has been reported that multiresistant
bacteria might be cultured from kidney transplant
patients as a consequence of prophylactic therapy, there-
fore antibiograms of the infecting microorganisms have
been suggested [1,3,16]. Antibiograms were performed
for infective bacteria in our study, in order to offer
more appropriate therapy to patients. Antibiograms in
these patients are useful to reduce employment of anti-
biotic therapy on unnecessary cases and to improve
antibiotic therapy on kidney transplanted patients.
Twenty-two percent of our isolates were resistant to
ciprofloxacin, which is used widely in kidney transplant
patients, although this was lower than the 50% resis-
tance reported by Senger et al. in 2007 [3]. In the pre-
sent study, ampicillin resistance was observed in 33% of
the Gram-negative strains. The main therapeutic options
Table 1 Characteristics of patients with renal allograft
Characteristics of the evaluated group Number of cases Percentage Significant Χ
2 test
Women with UTI 11 [22] 50%
Men with UTI 8 [30] 22% p = 0.042
Deceased donor with UTI 7 [10] 70%
Alive donor with UTI 12 [42] 28% p = 0.007
Rejection with UTI 3 [33] 9%
Rejection without UTI 2 [19] 10.5% N.S. p = 0.46
Patient survival after 5 years 49 [52] 94.23%
Graft function survival to present day 47 [52] 90.38%
Death and UTI 0 [5] 0%
Table 2 Patients with UTI and kidney allograft loss
Allograft survival to
present
Allograft
rejection.
(% )
With UTI 14 3 21.0%
Without
UTI
33 2 6.06%
Χ
2 test; N.S. p = 0.1709
Table 3 Isolated microorganisms from UTI from kidney
transplant patients
Isolated strains No. of cases Frequency (%)
E. coli 6 31.579
Candida spp. 4 21.053
Enterococcus spp. 2 10.526
A. calcoaceticus var. Anithratus 1 5.263
E. cloacae 1 5.263
K. oxytoca. 1 5.263
K. pneumoniae 1 5.263
M. morganii 1 5.263
P. aeruginosa 1 5.263
Micrococcus spp. 1 5.263
Total 19 100.000
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micin and fosfomycin. Cephalosporin showed intermedi-
ate resistance in our study, whereas, Lazinzka et al [29]
reported that 90% of Gram-negative strains isolated
from kidney transplant patients in Poland were suscepti-
ble to ceftriaxone and ceftazidime. These result might
explain the failure of the employed prophylaxis in
patients developing UTI. In fact, it is known that anti-
biotic resistance is a frequent medical problem due to
the injudicious use of these drugs; however an individual
antibiogram, as obtained in this study, gave a good ther-
apeutic alternative to patients who presented with UTI
after receiving a kidney allograft.
Surveillance of UTI in the first 3 months after surgery,
using urinary culture, leukocyte esterase stick and anti-
biograms, is a good way to reduce the risk of UTI in
transplant patients and the exit of the graft function,
especially those receiving deceased grafts or female
patients. In the present study, 3/19 patients with UTI
suffered kidney graft rejection, while only 2/33 patients
without UTI had graft rejection. This difference was not
statistically significant, which differs from previous stu-
dies that have stated that UTI might be a cause of graft
rejection [30]. Nevertheless ,i tm a yb ew o r t h w h i l et o
advise patients to continue with their clinical and bac-
teriological evaluation after surgery.
Conclusions
Surveillance of UTIs for the first 3 months is a reason-
able option for improving graft function free of kidney
infections and assuring the quality of life for the kidney
transplant population and the loss of graft function,
especially for female patients and those receiving suspi-
cious deceased grafts. Antibiograms give a good thera-
peutic alternative to patients who present with UTIs
after receiving a kidney allograft.
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